Introduction: The main therapeutic intervention for sickle cell disease (SCD) is hydroxyurea (HU).
INTRODUCTION
Sickle cell disease (SCD) is an inherited blood disease characterized by pain, fatigue, organ damage, and reduced quality of life (QOL). 1, 2 The disease primarily affects Americans of African descent, Abbreviations: CHW, community health worker; CLOTH, Community League of the Heights; ED, emergency department; HbF, fetal hemoglobin; HU, hydroxyurea; PDC, proportion of days covered; QOL, quality of life; SCD, sickle cell disease including Caribbean Latinos and other underserved communities. 3, 4 Offering hydroxyurea (HU), the sole FDA-approved treatment for SCD, for pediatric use is recommended as standard pediatric practice for patients with a severe phenotype. 5 HU use in children with SCD reduces symptoms and improves QOL for two sickle subtypes, HbSS and HbS-B 0 thalassemia. 5 Effects of HU are largely through induction of a dose-dependent increase in fetal hemoglobin (HbF). Antiinflammatory effects of HU also contribute to its clinical impact, such as reducing neutrophil count and inflammatory mediators. 6, 7 Despite its benefits, poor HU adherence in adolescents and young adults is common [8] [9] [10] [11] [12] [13] [14] and can be associated with increased healthcare utilization 8 and reduced health QOL. 14 Similar to medication use among underserved populations with other chronic conditions, barriers to adherence include cultural misalignment with medical staff [15] [16] [17] [18] and incomplete knowledge of drug benefit. 12, [15] [16] [17] Forgetting to take medication and lapses in teen self-efficacy are common self-reported patient barriers to adherence in chronic conditions. 12, [18] [19] [20] [21] Adherence may be improved by integration of use into a daily medication habit. 22 Improved adherence to HU through a developmentally appropriate self-managed habit may improve the health of youth with SCD. 23 We describe a two-site randomized pilot intervention, HABIT, to improve HU adherence in a sample of youth with SCD. The study focused on patients with apparent suboptimal HU adherence, as measured by decreased HbF responses compared to previous levels on comparable HU doses. Transition of responsibility for self-management should occur during adolescence. [24] [25] [26] Our intervention was led by culturally aligned community health workers (CHWs) and was loosely based on a previously successful pediatric asthma intervention. 27, 28 CHWs are an accepted mode of communitybased support for improving health in underserved communities and have improved medical adherence among adults with other chronic conditions. [28] [29] [30] [31] [32] Results of CHW-based patient support have not previously been reported in SCD or in CHW partnering with youthparent dyads. Here, we assessed if study dyads would work with CHWs toward the goals of improved understanding of SCD and HU, identifying and addressing barriers to medication adherence, building youthparent disease self-management partnerships, and identifying a cue on which a medication habit could be built. CHW support was augmented by tailored automated text message reminders that appeared as sent by the CHWs.
As no standard biomarker exists to assess HU adherence, 9, 11, 13, 33, 34 we used the highest historical HU-induced HbF at stable HU dose, "Personal best," as a target for an individualized self-management goal. 35, 36 In this context, clinic-based Personal best may be considered as comparable to study-based maximum tolerated dose. We have previously reported on the utility of this biomarker for tracking HU use in a retrospective sample of youth on HU therapy from these same two study sites. In that study, youth on stable HU doses were grouped as having stable or substantially decreased HbF from Personal best at a recent assessment. Reversing of other hematologic parameters affected by HU (e.g., hemoglobin, absolute neutrophil, and reticulocytes counts) and urgent hospital use over 1-year periods were found only in the group with greater decline from Personal best. 36 Primary aims of this pilot study were to assess the following: (1) Feasibility and acceptability of the randomized intervention and (2) the effect size on adherence relative to controls using a composite of primary endpoints to estimate the necessary sample size needed to power an efficacy trial. As an adherence study, the non-intervention arm was designed as an attention control. An attention control arm in this pilot intervention study was used to reduce study bias and to approximate an effect size upon which sample size for a future efficacy trial could be estimated. The results of these aims are reported here.
METHODS
All study procedures were approved by the Institutional Review Boards at each participating site. The study protocol has been described in detail elsewhere 35 and is briefly summarized below.
Subjects: Subjects 10-18 years of age and a parent (or legal guardian) were recruited from two pediatric sickle cell clinical sites, Columbia University Medical Center and Children's Hospital at Montefiore, both in New York City. Subjects were enrolled as youth-parent dyads.
Eligible patients had a ≥10% decrease in their HbF from their Personal best HbF during clinical care based on the average of ≥3 HbF levels during the year prior to study enrollment. 36 Additional eligibility criteria were as follows: youth with HbSS or HbS-B 0 thalassemia prescribed HU ≥18 months, not cognitively impaired (defined as >1 level below expected grade due to school performance issues), and youth and parent were able to speak and read in English or Spanish and were willing to use a cell phone with text message capability. All HbF values were determined by high-performance liquid chromatography and recorded only if at >90 days from transfusions. Dyads meeting eligibility criteria provided consent and/or assent that included release of pharmacy records for the 1 year prior to study entry through the duration of study participation. 35 Intervention: Randomization with 2:1 allocation to the intervention by a computerized random number generator was used to gain maximum feedback about the 6-month HABIT intervention. Subjects were blinded to study hypotheses, although not to group allocation. Upon Prescription refill adherence was measured as the PDC. 39 The PDC calculation is based on prescription fill dates and days supplied for each prescription refill. The denominator for the PDC is the number of days between the first and last fill dates of the medication during the measurement period. PDC was calculated for the 12 months prior to study entry and for the 6 months of study participation.
At study completion, youth and parents completed a 5-point evaluation survey about usefulness of the educational materials, with responses ranging from "strongly disagree" to "strongly agree." Intervention dyads were also asked about their perceptions regarding working with the CHW and utility of the text messages.
Data analysis: Data were analyzed using SAS 9.3 (Cary, NC). Descriptive statistics were used to profile outcome measures at each data collection point for the intervention and control groups. Baseline group characteristics and adherence measures were compared using chi-square, Fisher's exact, and Wilcoxon rank sum tests. Evaluation survey responses were dichotomized as strongly agree/agree and strongly disagree/disagree/not sure. A growth model, 41 a type of linear mixed model with random intercepts and slopes, was used to examine the difference in trend of improvement to Personal best, controlling for group assignment and month of study.
RESULTS

Enrollment and retention:
Of 74 youth screened at two study sites, 48 met all inclusion/exclusion criteria. Of these, 28 dyads (58%) participated in the study (targeted 30 dyads). Subject attrition was 10.7%
(two intervention dyads and one control dyad). Reasons for dyad attrition were incarceration (one youth), illicit drug activity (one youth), and study procedures perceived as too burdensome (one parent).
The multiethnic sample of 28 dyads was similar in most demographic characteristics (Table 1) . On average, youth were 14.3 ± 2.6 years, 43% female and 50% Hispanic. The majority (64.3%) of parents was single and/or separated from a spouse, had a high school education or less (57%), and was employed full or part time (71.4%). Spanish language surveys were selected for use by 42% of parents and 25% of youth.
By parental self-report for the 1-year prestudy enrollment period, urgent hospital resource use was similar between the two groups: approximately 60% of each group reported having been hospitalized and having one or more ED visits (Table 1) . Of those receiving urgent care, there was no difference by group in the numbers of admissions and ED visits. 
HU adherence measures
Fetal hemoglobin: Personal best HbF was similar between the two study groups (P = 0.88) ( Table 2) . At study baseline, while mean HbF was similar (P = 0.25), there was less decrease from Personal best HbF in the
Control Group (n = 10) n % n % P v a l u e s Fig. 1 ). Controlling for intervention month and group assignment, the intervention group progressed to Personal best by 2.3% per month during months 0-4 (P = 0.30). Four (one control and three intervention) subjects who completed the study (16%) exceeded their Personal best HbF.
Clinical data: Parents reported the numbers of ED visits and hospitalizations for their child during the 1 year prior to study start (Table 1) . 3) for the 6-month intervention (Table 2) .
TA B L E 2 Measures of HbF during the intervention by the subject group
By the study group, blood count values that are sensitive to HU such as absolute neutrophil count were not different at Personal best, first (M0) and last (M6) study visits (Table 3) . HU dose was significantly higher in the Intervention group at M0.
HU pharmacy refill:
Results were consistent with Personal best when adherence was measured using HU pharmacy refill data ( Table 2) .
PDC for the year prior to study entry was 64.6 ± 32.6% and 79.4 ± 28.2% for the intervention and control groups, respectively (P = 0.15).
At study completion, adherence modestly improved to 75.6 ± 20.7% (14.6%) and to 82.9 ± 20.5% (4.5%) for the intervention and control groups, respectively, with no significant difference between groups (P = 0.33).
Morisky self-reports of HU adherence:
Youth and parents in both groups uniformly reported low scores indicating good adherence. No significant differences were seen at month 0 for youth (1.6 ± 1.1 and 1.4 ± 1.1 for intervention and control groups, respectively) and their parents (0.7 ± 0.8 and 1.1 ± 1.4) and at month 6 for youth (1.1 ± 1.2 and 1.0 ± 1.1) and parents (0.6 ± 1.0 and 0.6 ± 0). Overall, 17.9% of youth and 10.7% of parents reported their adherence to HU as low.
Scores were inconsistent with the two other methods used to assess HU adherence.
Text messaging: Three parents and six youth required a mobile telephone for the texting (Table 4) (Table 4) . Nonetheless, nearly all (93.3% of parents, 86.7% of youth) thought that the texts were helpful reminders for taking HU. A parent reported "I liked that the text was a set time every day and always on time"; a youth stated that the texts "reminded me every night to take my HU" and "I never forget my medication." When dislikes about the texts were solicited, one youth stated that "sometimes texts me at the wrong moment" and another that "I don't like that they came mostly every day."
DISCUSSION
The HABIT pilot trial demonstrated feasibility and acceptability of the intervention. Youth-parent dyads valued the intervention and were This finding suggests that pressing psychosocial issues and other unmet needs existed despite clinic-based resources. 32 CHWs seemed to have provided an environment for dyads to address issues that can be barriers to maintaining adherence.
Dyads from both study groups reported having learned something new about SCD and HU from the education handouts. This finding suggested that information routinely conveyed by clinical providers may not be entirely effective in reaching youth and their parents. Effectively communicating fundamental health concepts may require culturally and linguistically aligned messengers and materials. 32, 42 Differences in deviation from HbF between study groups occurred despite randomization, especially in subject deviation from Personal best at month 0. If or how these differences may have impacted the
TA B L E 3
Blood count measurements at Personal best HbF, study initiation month 0 (M0), and at completion (M6) by the study group Adolescence is a critical time to improve adherence as preparation for the transition to chronic disease self-management. 24, [43] [44] [45] [46] Our retrospective assessment of youth from these two clinical sites suggested that a large proportion had suboptimal HU adherence. 36 The HABIT intervention focused on HU adherence through structured but tailored interactions with CHWs, supplemented by customized text message reminders, and encouraged developmentally appropriate youth-parent partnerships for self-management. Intervention trials to improve adherence among underserved children with chronic illness reinforce the importance of community-based support. 28 Adolescents with SCD have previously accepted daily text reminders aimed to improve HU adherence. 47, 48 Trials to improve HU adherence are limited and, to date, have focused largely on HbF levels 42 Here, we utilize outcomes of HbF, selfreported formation of a daily medication habit, and parent-child cooperative self-management. The use of dyad report of the Morisky scale for adherence was found to be inconsistent with objective biomarker and pharmacy refill data, a finding that is generally consistent with selfreported adherence. 11, 49 Study limitations included the modest sample size that limited statistical power and ability to examine specific factors associated with response to the intervention, as well as differences between study groups despite randomization. Study arm assignment could not be blinded. HU dose adjustments were not standardized during the study, although few minor changes were made for subject weight at both study sites. Monthly clinic visits were more frequent than the standard of visits every 2-3 months for patients on HU. Potential effects on adherence would be applicable to subjects in both study arms.
As HbF induction with HU can take several months to occur, the 6- 
